Brensocatib (Brinsupri; Insmed) gains FDA approval as the first treatment for bronchiectasis, offering hope to patients with ...

The FDA granted approval to brensocatib for treating adults and children aged at least 12 years with non-cystic fibrosis ...

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...

Amber Specialty Pharmacy, a pioneer in specialty pharmacy for more than 25 years, today announced it is now dispensing BRINSUPRI™ (brensocatib) following the medication’s U.S. Food and Drug ...

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has ...

A first-in-class reversible dipeptidyl peptidase-1 (DPP-1) inhibitor, brensocatib addresses the underlying inflammatory ...

Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permane ...

A new federal study is linking the ability to quit smoking with longer-term success from the grip of drug or alcohol ...

Brinsupri is a first-in-class DPP1 inhibitor that has been found to inhibit activation of neutrophil enzymes that drive chronic airway inflammation in non-cystic fibrosis bronchiectasis.

The US Food and Drug Administration approved New Jersey, USA-based Insmed’s (Nasdaq: INSM) fibrosis bronchiectasis (NCFB), a ...